Stock Pulse
Thermo Fisher Scientific (TMO) demonstrated strong Q4 2024 financial performance with 5% revenue growth, reaching $11.4 billion, and generated over $7.3 billion in free cash flow [1], [3], [6], [7]. The company acquired SOLV's Purification and Filtration business for $4.1 billion, enhancing its bioprocessing capabilities [1], [3]. Despite macroeconomic headwinds and declining COVID-19 testing demand impacting recent stock performance [2], [5], the launch of new products like the Krios 5 Cryo-TEM and continued innovation are generating positive sentiment [4], [9]. While analysts are bullish on long-term growth due to TMO's diverse offerings and leadership in the life sciences sector [1], some suggest that other investments like AI stocks may offer higher short-term returns [1], [3]. A director also recently received phantom stock units as part of a deferred compensation plan [11].